Relmada Therapeutics Operating Income 2013-2024 | RLMD

Relmada Therapeutics operating income from 2013 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Relmada Therapeutics Operating Income 2013-2024 | RLMD

Relmada Therapeutics operating income from 2013 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.7B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$19.3B
Merck (MKKGY)$18.8B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.4B
Summit Therapeutics (SMMT)$13.6B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$11.8B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.6B
Madrigal Pharmaceuticals (MDGL)$7.2B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.9B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.3B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
Evotec AG (EVO)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.7B
Recursion Pharmaceuticals (RXRX)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B